Rein Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
RNTX$0.62+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $4,445 | $3,215 |
| Prepaid expenses and other current assets | 1,008 | 1,111 |
| Total current assets | 5,453 | 4,326 |
| Goodwill | 6,330 | 6,330 |
| Intangible assets | 13,500 | 13,500 |
| Other non-current assets | 1,005 | 2 |
| Total assets | $26,288 | $24,158 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $6,263 | $3,976 |
| Accrued expenses and other current liabilities | 2,451 | 2,204 |
| Notes payable, net | 4,923 | — |
| Total current liabilities | 13,637 | 6,180 |
| Deferred tax liability | 1,060 | 1,060 |
| Total liabilities | 14,697 | 7,240 |
| Commitments and contingencies (Note 13) | ||
| Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized at March 31, 2026 and at December 31, 2025; 24,610 shares issued and 12,232 shares outstanding at March 31, 2026 and at December 31, 2025 | 45,005 | 45,005 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2026 and at December 31, 2025; 28,039,032 shares and 27,550,222 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 114 | 113 |
| Additional paid-in capital | 373,643 | 373,133 |
| Accumulated other comprehensive loss | (62) | (62) |
| Accumulated deficit | (407,109) | (401,271) |
| Total liabilities, convertible preferred stock and stockholders’ equity | $26,288 | $24,158 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.